Merck CEO Goes On Defense, Cuts Jobs
December 15, 2004 07:37

In the wake of the Vioxx withdrawal, Gilmartin says, Merck is substantially changing "every aspect" of its business. ... Gilmartin also defended Merck against charges that it mishandled Vioxx, which was withdrawn from the market in September after a Merck study... (Read this Vioxx Article)

TRENTON, N.J. - Pharmaceutical giant Merck & Co., under siege over revenues lost since it recalled arthritis drug Vioxx, will have cut about 5,100 jobs by year's end, 700 more than first planned, and will slash costs by $2.4 billion over four years, chairman... (Read this Vioxx Article)

With the recent recall of Vioxx, a critical challenge facing the Cox-2 inhibitor markets in the United States is the need to conclusively demonstrate the safety of these drugs in long-term use. "Post recall, gaining the approval of the Food and Drug Administration... (Read this Vioxx Article)